Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Cardiology Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

International Experiences with New Presbyopia-Correcting IOLs – Enduring

By: Eric D. Donnenfeld, MD; Iqbal Ike K. Ahmed, MD; Gerd U. Auffarth, MD, PhD, FEBO; Paul Harasymowycz, MD

Webinar Credits: 1

This course is designed to educate ophthalmologists on the use of next generation presbyopia-correcting IOLs, including hybrids of advanced monofocals, EDOFs and multifocals from multiple manufacturers. Featuring first-hand accounts from an international group of faculty, US doctors will be able to learn about the next generation IOL designs and outcomes through real-world cases and group discussion.

Expiration Date: Friday, December 31, 2021
Release Date: December 23, 2020

Learning Objectives

Upon completion of this activity, the participant should be able to:

  1. Evaluate international experiences with matching patient visual needs to new presbyopia-correction innovations from doctors outside the United States.
  2. Describe how new presbyopia-correcting innovations and technologies help to maximize vision at all distances.
  3. Describe how new presbyopia-correcting innovations and technologies help to maximize visual quality and mitigate dysphotopsia.

 

Accreditation and Designation Statement

Provided by Evolve Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education, LLC, and The Fundingsland Group. Evolve Medical Education, LLC is accredited by the ACCME to provide continuing medical education for physicians.​

Designation Statement

Evolve Medical Education, LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.​

 

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM

Recommended internet speed 5Mbps+

 

Faculty and Disclosures

Eric D. Donnenfeld, MD

Moderator
Partner, Ophthalmic Consultants of Long Island and Connecticut
Clinical Professor of Ophthalmology, New York University
Trustee, Dartmouth Medical School

Iqbal Ike K. Ahmed, MD

Assistant Professor, University of Toronto
Fellowship Director, Glaucoma and Anterior Segment Surgery Fellowship, University of Toronto
Research Director, Kensington Eye Institute, University of Toronto
Division Head, Ophthalmology, Trillium Health Partners, Mississauga, Ontario
Medical Director, Prism Eye Institute
Co-Medical Director, TLC Oakville

Gerd U. Auffarth, MD, PhD, FEBO

Chairman, Department of Ophthalmology, Heidelberg University Eye Hospital
Director (Head), International Vision Correction Research Centre
Director (Head), David J. Apple Center for Vision Research

Paul Harasymowycz, MD

Associate Professor, University of Montreal
Medical Director Bellevue Ophthalmology Clinics and Montreal Glaucoma Institute

It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

  • Eric D. Donnenfeld, MD, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant:  Allegro, Allergan , Alcon, Avellino Labs, Bausch & Lomb, CorneaGen, Covalent, CRST, BVI, Blephex, Dompe, ELT Sight, EyePoint Pharma, Foresight, Glaukos, Ivantis, Johnson & Johnson, Kala, Katena, Lacripen, LensGen,  Mati Pharmaceuticals,  MDBackline, Merck, Mimetogen, Nanowafer, Novabay, Novartis, Novaliq, Ocular Innovations, Oculis, Odyssey, Omega Ophthalmics, Oyster Point Therapeutics, Pfizer, Pogotec, Ocuhub, Omeros, PRN , RegenerEyes, ReTear, RPS, Shire, Strathspey  Crown, SUN, Surface, Tarsus, Tearlab, Tearscience, Thea, TLC Laser Centers, Veracity, Versant Ventures, Visionary Venture, Visus, and Zeiss. Stock Shareholder: Avedro, CorneaGen, Covalent,  ELT Sight, EyePoint Pharma Glaukos, Ivantis, Lacripen , LensGen, Mati Pharmaceuticals, MDBackline, Mimetogen,  Novabay, Ocuhub, Ocular Innovations Oculis, Orasis Pogotec, RegenerEyes, ReTear, RPS , Strathspey  Crown, Surface, Tarsus, Tearlab, Veracity, Versant Ventures, Visionary Ventures, and Visus.
  • Iqbal Ike K. Ahmed, MD, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Aequus, Aerie, Akorn, Alcon, Allergan, Aquea Health, ArcScan, Bausch Health, Beaver Health, Beaver Visitec, Camras Vision, Zeiss, CorNeat Vision, Ellex, ELT Sight, ElutiMed, Equinox, Genentech, Glaukos, Gore, InjectSense, Iridex, iStar, Ivantis, Johnson & Johnson Vision, KeLoTec, LayerBio, Leica, Long Bridge Medical, MicroOptx, MST Surgical, Mynosys, New World Medical, Ocular Instruments, Ocular Therapeutix, PolyActiva, Sanoculis, Santen, Science Based Health, Sight Sciences, Smartlens, Stroma, Thea, ViaLase, Vizzario; Speaker Honoraria: Alcon, Allergan, Zeiss, Johnson & Johnson Vision, MST Surgical, Mundipharma; Research Grants: Aerie, Alcon, Allergan, Camras, Glaukos, Johnson & Johnson Vision, New World Medical, Santen
  • Gerd U. Auffarth, MD, PhD, FEBO, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Alcon, Johnson & Johnson Vision; Lecture Fees: Johnson & Johnson Vision, Biotech, Zeiss, Hoyga, Kowa, Oculentis, Oculus, Rayner, Santen, Sifi; Travel Fees: Alcon, Johnson & Johnson Vision, Zeiss, Hoya, Kowa, Oculentis, Rayner, Santen, Sifi; Research Grants: Acufocus, Johnson & Johnson Vision, Anew, Biotech, Zeiss, Contamac, Hoya, Kowa, Oculentis, Oculus, Physiol, Rayner, Santen, Sifi.
  • Paul Harasymowycz, MD, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Allergan, Alcon, Bausch Health, Novartis, Glaukos, Ivantis, Thea, Santen, Iridex, New World Medical, Johnson & Johnson Vision, Aequus; Grant/Research Support: Allergan, Bausch Health, Glaukos, Ivantis, Thea, and Johnson & Johnson Vision.

EDITORIAL SUPPORT DISCLOSURES
The staff and planners from Evolve and The Fundingsland Group have no financial relationships with commercial interests.  Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.

 

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, Alcon, Johnson & Johnson Vision, or Orasis Pharmaceuticals.

Pretest

  • a. USb. Canadac. Latin Americad. Europe/Middle Easte. Asia/Australia
  • a. <250 eyesb. 250-500 eyesc. 501-1,000 eyesd. >1,000 eyese. Don’t do cataract surgery
  • a. Noneb. 1-5%sc. 6-10%d. 11-30%e. Over 30%
  • a. Visual qualityb. Spectacle independencec. Minimizing dysphotopsia
  • a. Very confidentb. Confidentc. Neutrald. Not so confidente. Not confident at all

Next

Test

Instructions

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Step 1 of 2

  • a. Visual qualityb. Spectacle independencec. Minimizing dysphotopsia
  • a. Very confidentb. Confidentc. Neutrald. Not so confidente. Not confident at all
  • a. Significant increaseb. Moderate increasec. Minor increased. No change
  • AgreeNeutralDisagree
    Evaluate international experiences with matching patient visual needs to new presbyopia-correction innovations from doctors outside the United States.
    Describe how new presbyopia-correcting innovations and technologies help to maximize vision at all distances.
    Describe how new presbyopia-correcting innovations and technologies help to maximize visual quality and mitigate dysphotopsia.
Back